Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(37.5%)

Phase 3

3(37.5%)

Phase 2

2(25.0%)

8Total

Phase 1(3)

Phase 3(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT05995405Phase 3Active Not Recruiting

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

Role: lead

NCT05418348Phase 1Completed

Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects

Role: lead

NCT05531890Phase 1Unknown

Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects

Role: lead

NCT05517486Phase 1Unknown

Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects

Role: lead

NCT03361501Phase 3Completed

A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

Role: lead

NCT03398005Phase 3Completed

A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

Role: lead

NCT01455844Phase 2Completed

TRIal For Efficacy of Capre on hyperTriglyceridemiA

Role: lead

NCT01516151Phase 2Completed

Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia

Role: lead

All 8 trials loaded